2,3-dinor-thromboxane b2 has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrow, SE; Benjamin, N; Brassfield, T; Ritter, JM; Stratton, PD | 1 |
| Fitzgerald, DJ; FitzGerald, GA; Fragetta, J | 1 |
1 trial(s) available for 2,3-dinor-thromboxane b2 and Coronary Disease
| Article | Year |
|---|---|
Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Naphthalenes; Platelet Activation; Pravastatin; Risk Factors; Thromboxane B2 | 1991 |
1 other study(ies) available for 2,3-dinor-thromboxane b2 and Coronary Disease
| Article | Year |
|---|---|
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Coronary Disease; Coronary Thrombosis; Dibenzothiepins; Dogs; Male; Platelet Aggregation; Prostaglandin Endoperoxides; Prostaglandin Endoperoxides, Synthetic; Thromboxane B2; Thromboxane-A Synthase | 1988 |